17,261 trials
Lymphoma, Large-Cell, Anaplastic · Carcinoma, Non-Small-Cell Lung
Primary: Recommended Phase 2 Dose (RP2D) of Brigatinib — NA mg
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
Uveitis
Primary: Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16 — 30.0; 46.1 Percentage of participants — p=0.2354
Urinary Tract Infections · Acute Pyelonephritis
Primary: Number of Participants With Clinical and Microbiological Response — 45; 46; 35 Participants
Lung Neoplasms
Primary: Progression-free Survival — 12.78; 11.17 Months — p=0.0891
Lung Cancer
Primary: Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008]) — 0; 0; 2 DLTs
Bladder Cancer
Primary: EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib — -0.29; 0.128 fold change
Rheumatoid Arthritis
Primary: American College of Rheumatology (ACR) 20 Response Rate at Week 2 — 45.0; 43.2; 46.2; 47.4 percentage of participants
Familial Amyotrophic Lateral Sclerosis
Primary: Mean Change in SOD1 CSF — 6.8 ng/ml
Sarcoma, Kaposi
Primary: Overall Response Rate (ORR) of Six Cycles of Liposomal Doxorubicin Combined With Bevacizumab in Patients With Advanced KS. — 50; 67 percentage of participants
Treatment of Induced Panic Attack
Primary: Number of Participants With Doxapram-induced Panic Attack — 14; 9 Participants — p=0.200
End Stage Renal Disease
Primary: Mean Maximum Concentration (Cmax) of Ertapenem in Hemodialysis Patients — 663.1 mcg/ml
Thalassemia Major
Primary: Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC) — -5.934 % change of hematocrit-adjusted volume
Mild Cognitive Impairment · Dementia
Primary: Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo — 14; 21 Participants — p=<0.16
Hodgkin Disease · Hodgkin's Lymphoma · Lymphoma
Primary: Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity — 0; 3 participants